Brian Abrahams
Stock Analyst at RBC Capital
(2.36)
# 2,475
Out of 4,711 analysts
430
Total ratings
42.36%
Success rate
-1.4%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLT Applied Therapeutics | Maintains: Sector Perform | $4 → $1.5 | $0.88 | +70.44% | 5 | Dec 20, 2024 | |
| HOOK HOOKIPA Pharma | Downgrades: Sector Perform | $48 → $2 | $2.02 | -0.99% | 11 | Dec 20, 2024 | |
| GILD Gilead Sciences | Reiterates: Sector Perform | $84 | $92.57 | -9.26% | 29 | Dec 11, 2024 | |
| NMRA Neumora Therapeutics | Reiterates: Outperform | $29 | $10.85 | +167.28% | 5 | Nov 22, 2024 | |
| SAGE Sage Therapeutics | Upgrades: Sector Perform | $4 | $5.61 | -28.70% | 21 | Nov 21, 2024 | |
| INCY Incyte | Maintains: Sector Perform | $80 → $74 | $68.84 | +7.50% | 19 | Nov 19, 2024 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $32 → $31 | $13.50 | +129.63% | 3 | Nov 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $437 → $451 | $397.27 | +13.52% | 48 | Nov 5, 2024 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $10 | $7.57 | +32.10% | 15 | Nov 5, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,260 → $1,215 | $701.85 | +73.11% | 30 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $26.76 | +12.11% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $1 | $0.23 | +334.78% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $182 | $118.97 | +52.98% | 31 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $6.90 | +189.86% | 14 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $133 | $135.42 | -1.79% | 16 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $34 | $46.24 | -26.47% | 17 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $108 | $83.45 | +29.42% | 18 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $292 → $269 | $146.47 | +83.66% | 33 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $82 | $13.00 | +530.77% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $38.63 | +42.38% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $24 | $15.22 | +57.69% | 9 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3 | $0.64 | +372.44% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $7.94 | +51.13% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.16 | +207.26% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $45 | $13.21 | +240.65% | 11 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $6.28 | +138.85% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.19 | +656.30% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $41.85 | -21.15% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $44.22 | - | 4 | Dec 4, 2017 |
Applied Therapeutics
Dec 20, 2024
Maintains: Sector Perform
Price Target: $4 → $1.5
Current: $0.88
Upside: +70.44%
HOOKIPA Pharma
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $2.02
Upside: -0.99%
Gilead Sciences
Dec 11, 2024
Reiterates: Sector Perform
Price Target: $84
Current: $92.57
Upside: -9.26%
Neumora Therapeutics
Nov 22, 2024
Reiterates: Outperform
Price Target: $29
Current: $10.85
Upside: +167.28%
Sage Therapeutics
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $5.61
Upside: -28.70%
Incyte
Nov 19, 2024
Maintains: Sector Perform
Price Target: $80 → $74
Current: $68.84
Upside: +7.50%
Contineum Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $31
Current: $13.50
Upside: +129.63%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Sector Perform
Price Target: $437 → $451
Current: $397.27
Upside: +13.52%
BioCryst Pharmaceuticals
Nov 5, 2024
Reiterates: Outperform
Price Target: $10
Current: $7.57
Upside: +32.10%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,260 → $1,215
Current: $701.85
Upside: +73.11%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $26.76
Upside: +12.11%
Oct 25, 2024
Maintains: Sector Perform
Price Target: $3 → $1
Current: $0.23
Upside: +334.78%
Oct 21, 2024
Reiterates: Outperform
Price Target: $182
Current: $118.97
Upside: +52.98%
Oct 18, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $6.90
Upside: +189.86%
Oct 8, 2024
Reiterates: Sector Perform
Price Target: $133
Current: $135.42
Upside: -1.79%
Oct 4, 2024
Maintains: Sector Perform
Price Target: $32 → $34
Current: $46.24
Upside: -26.47%
Oct 4, 2024
Maintains: Outperform
Price Target: $106 → $108
Current: $83.45
Upside: +29.42%
Oct 4, 2024
Maintains: Outperform
Price Target: $292 → $269
Current: $146.47
Upside: +83.66%
Sep 20, 2024
Reiterates: Outperform
Price Target: $82
Current: $13.00
Upside: +530.77%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $38.63
Upside: +42.38%
Aug 9, 2024
Maintains: Sector Perform
Price Target: $28 → $24
Current: $15.22
Upside: +57.69%
Aug 7, 2024
Reiterates: Outperform
Price Target: $3
Current: $0.64
Upside: +372.44%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $7.94
Upside: +51.13%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $7.16
Upside: +207.26%
May 7, 2024
Maintains: Outperform
Price Target: $54 → $45
Current: $13.21
Upside: +240.65%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $6.28
Upside: +138.85%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.19
Upside: +656.30%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $41.85
Upside: -21.15%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $44.22
Upside: -